Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cisplatin + nab-paclitaxel + nivolumab with radiotherapy after TURBT in non-metastatic muscle-invasive bladder cancer (CNN-BC)
2024-518937-26-00Phase 2Authorised
- Sponsor
- Policlinico Gemelli
- Start
- Nov 2024
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of nivolumab, cisplatin and nab-paclitaxel in bladder cancer, sponsored by Policlinico Gemelli. Primary endpoint: 1-year disease-free survival. Planned start Nov 2024; status: authorised.
02
Drugs
03
Conditions
bladder cancer
Beyond the preview
Go deeper on 2024-518937-26-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518937-26-00.